美国 - 英文 - NLM (National Library of Medicine)

a-s medication solutions - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - humira is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. humira can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). humira is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. humira can be used alone or in combination with methotrexate. humira is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. humira can be used alone or in combination with non-biologic dmards. humira is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. humira is indicated for reducing signs and symptoms and indu

美国 - 英文 - NLM (National Library of Medicine)

samsung bioepis co., ltd. - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - imraldi is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. imraldi can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). imraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and ≥ 30 kg (66 lbs). imraldi can be used alone or in combination with methotrexate. imraldi is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. imraldi can be used alone or in combination with non-biologic dmards. imraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. imraldi is indicated for reduci

美国 - 英文 - NLM (National Library of Medicine)

merck sharp & dohme corp. - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - hadlima is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. hadlima can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). hadlima is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older. hadlima can be used alone or in combination with methotrexate. hadlima is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. hadlima can be used alone or in combination with non-biologic dmards. hadlima is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. hadlima is indicated for reducing signs and symptoms

美国 - 英文 - NLM (National Library of Medicine)

amgen usa inc. - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - amjevita is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. amjevita can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). amjevita is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. amjevita can be used alone or in combination with methotrexate. amjevita is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. amjevita can be used alone or in combination with non-biologic dmards. amjevita is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. amjevita is indicated for the treatment of mod

美国 - 英文 - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - cyltezo is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. cyltezo can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). cyltezo is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. cyltezo can be used alone or in combination with methotrexate. cyltezo is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. cyltezo can be used alone or in combination with non-biologic dmards. cyltezo is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. cyltezo is indicated for the treatment of moderately

美国 - 英文 - NLM (National Library of Medicine)

fresenius kabi usa, llc - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - idacio is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. idacio can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). idacio is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. idacio can be used alone or in combination with methotrexate. idacio is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. idacio can be used alone or in combination with non-biologic dmards. idacio is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. idacio is indicated for the treatment of moderately to sever

美国 - 英文 - NLM (National Library of Medicine)

organon llc - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - hadlima is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. hadlima can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). hadlima is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. hadlima can be used alone or in combination with methotrexate. hadlima is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. hadlima can be used alone or in combination with non-biologic dmards. hadlima is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. hadlima is indicated for the treatment of moderately

以色列 - 英文 - Ministry of Health

dexcel ltd, israel - adalimumab - solution for injection - adalimumab 50 mg/ml - adalimumab - rheumatoid arthritis: hulio in combination with methotrexate is indicated for:-the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.-the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.hulio can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.adalimumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.axial spondyloarthritis: ankylosing spondylitis (as): hulio is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.axial spondyloarthritis without radiographic evidence of as: hulio is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as, but with objective signs of inflammation by radiological and/or laboratory tests including mri and serum crp levels , who have had an inadequate response to, or are intolerant to, non-steroidal anti-inflammatory drugs. psoriatic arthritis: hulio is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti rheumatic drug therapy has been inadequate. adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.psoriasis: hulio is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.hidradenitis suppurativa (hs): hulio is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hs therapy.crohn’s disease:hulio is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy. hulio is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. ulcerative colitis: hulio is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis: hulio is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.intestinal behcet's disease: hulio is indicated for the treatment of intestinal behcet’s disease in patients who have had an inadequate response to conventional therapy.

美国 - 英文 - NLM (National Library of Medicine)

coherus biosciences inc - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - yusimry is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. yusimry can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). yusimry is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. yusimry can be used alone or in combination with methotrexate. yusimry is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. yusimry can be used alone or in combination with non-biologic dmards. yusimry is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. yusimry is indicated for the treatment of moderately

美国 - 英文 - NLM (National Library of Medicine)

a-s medication solutions - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - humira is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. humira can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards).  humira is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. humira can be used alone or in combination with methotrexate. humira is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. humira can be used alone or in combination with non-biologic dmards. humira is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. humira is indicated for the treatment of moderately to seve